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Abstract
Background: Increasing nosocomial pathogen resistance to available antimicrobial agents is of
growing concern. While higher MICs can diminish antimicrobial effectiveness, dose adjustments
often mitigate this effect. This study's objective was to ascertain whether MICs among major
pathogens in the ICU to several commonly used agents have increased enough to significantly
impact their ability to achieve bactericidal effect.
Methods: Cefepime, ceftriaxone, imipenem and piperacillin-tazobactam MICs were determined
with 74,394 Gram-negative bacilli obtained from ICU patients with various infections in the US
between 1993 and 2004. Results were grouped into four 3-year periods. The predicted cumulative
fraction of response (CFR) was estimated based on patient-derived pharmacokinetic values and
Monte Carlo simulation. Trends in CFR over the four study periods were assessed using the
Cochran-Armitage test. The primary analysis included all organisms combined; Pseudomonas
aeruginosa and Acinetobacter species were also evaluated individually.
Results: In the primary analysis, imipenem 500 mg q6h showed CFRs from 87% to 90% across all
four study periods, with a trend toward slightly improved bactericidal target attainment (p < 0.01).
CFRs for cefepime 2 g q12h and piperacillin-tazobactam 4.5 g q6h both declined by 2% (p < 0.01
and p < 0.05, respectively), reflecting upward shifts in the underlying MIC distributions. Ceftriaxone
had <52% CFR for all regimens in all periods, with no significant trend. Against P. aeruginosa,
significant declines in CFR were seen for (range, p-value): imipenem 1 g q8h (82%–79%, p < 0.01),
cefepime 1 g q12h (70%–67%, p < 0.01), cefepime 2 g q12h (84%–82%, p < 0.05), piperacillin-
tazobactam 3.375 g q6h (76%–73%, p < 0.01), piperacillin-tazobactam 4.5 g q8h (71%–68%, p <
0.01), and piperacillin-tazobactam 4.5 g q6h (80%–77%, p < .01). Against Acinetobacter spp., all
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regimens of imipenem, cefepime and piperacillin-tazobactam showed significant declines in CFR
over time (p < 0.01).
Conclusion: Our observations suggest that as a result of increasing antimicrobial resistance
among ICU pathogens in the US, drug effectiveness, assessed as a function of individual agents'
ability to attain pharmacodynamic targets, has declined, especially with P. aeruginosa and
Acinetobacter spp. Cefepime 2 g q8h and imipenem were the most potent agents against these
species, respectively. More aggressive dosing of all of the agents characterized could preserve their
clinical utility, but this must be balanced with safety and tolerability issues by the physician.
Introduction
Surveillance studies have revealed increasing rates of
resistance among bacteria commonly implicated in seri-
ous hospital infections; resistant pathogens are associated
with higher mortality rates than are susceptible organ-
isms[1,2]. As the pipeline of new antimicrobial agents for
Gram-negative pathogens shrinks, the longevity of exist-
ing compounds becomes a matter of primary concern[3].
Our earlier work has shown that pharmacokinetic/phar-
macodynamic (PK/PD) modeling based on Monte Carlo
simulations can be used reliably to predict the ability of
antimicrobial regimens to achieve maximum bactericidal
effect against organisms implicated in nosocomial infec-
tions[4]. Further, we have demonstrated that alterations
in dose can extend the coverage of many current com-
pounds[5,6].
Using Monte Carlo analyses, the objective of the current
study was to use PK/PD modeling to assess the profile of
activity of four antimicrobial agents commonly used to
treat serious infections – imipenem, ceftriaxone, cefepime
and piperacillin-tazobactam – versus a large collection of
bacteria recovered from patients in the intensive care unit
(ICU) setting in the United States between 1993 and
2004. These organisms had been characterized as part of
the Merck Intensive Care Unit Surveillance Survey (ISS)
Program. Secondly, we attempted to determine if the
activity profile of any of these antimicrobial agents had
diminished over time. A third objective was to determine
the effect of dose selection on the activity profile of the
agents.
Methods
This investigation employed Monte Carlo simulation
techniques to estimate the relative probability that various
antimicrobial agents would achieve maximally effective
(i.e. bactericidal) exposures against isolates of Gram-neg-
ative bacilli recovered from patients with infection in the
ICU. A PK model was developed for each compound and
then used in a simulation to incorporate patient variabil-
ity. The model, the input parameters, and the simulation
technique are described below. The following antibiotic
regimens were examined (administered as 30-minute
intravenous infusions): cefepime 1 gram (1 g) every
twelve hours (q12h), 2 g q12h and 2 g q8h; ceftriaxone 1
g q24h and 2 g q24h; imipenem 500 mg q6h and 1 g q8h;
and piperacillin/tazobactam 3.375 g q6h, 4.5 g q8h and
4.5 g q6h.
Microbiology
MICs for bacterial isolates used in the analysis were
obtained from the ISS Program from 1993 to 2004. A total
of 44 different species were characterized. The 11 most
commonly recovered species (which account for 94% of
the tested population) are displayed in Table 1. For each
compound, MIC results from all organisms tested were
grouped to form one MIC frequency distribution for four
intervals of three years each: 1993–1995, 1996–1998,
1999–2001, and 2002–2004. The MIC distributions were
incorporated into the analysis as described in the follow-
ing section, "Cumulative Fraction of Response." This sce-
nario (all isolates included) was modeled in the primary
analysis. Additionally, MIC distributions for two individ-
ual species, P. aeruginosa and Acinetobacter spp, were simi-
larly divided into four intervals of the same 3-year
periods. These groupings were used for sub-analyses of
those species.
Table 1: Eleven (11) most commonly recovered species 
(constituting 94% of the tested population) by frequency 
extracted from the Merck ICU Surveillance Program from 1993 
to 2004 (Total of all isolates: 74,394).
Organism Number (%) Cumulative frequency
Pseudomonas aeruginosa 16,482 (22) 22.2%
Escherichia coli 13,961 (19) 40.9%
Klebsiella pneumoniae 10,571 (14) 55.1%
Enterobacter cloacae 6,779 (9) 64.2%
Acinetobacter spp. 4,642 (6) 70.5%
Serratia marcescens 4,112 (6) 76.0%
Enterobacter aerogenes 3,307 (4) 80.5%
Stenotrophomonas maltophilia 3217 (4) 84.8%
Proteus mirabilis 3,011 (4) 88.8%
Klebsiella oxytoca 2,018 (3) 91.5%
Citrobacter freundii 1,483 (2) 93.5%Annals of Clinical Microbiology and Antimicrobials 2007, 6:11 http://www.ann-clinmicrob.com/content/6/1/11
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Pharmacokinetic model
A two-compartment multiple dose model was developed
to determine the 24-hour concentration-time profile at
steady-state for each drug regimen. PK parameters were
used as input variables, and included total body clearance
(CLT), volume of the central compartment (Vc), and the
microtransfer rate constants between the central and
peripheral compartments (k12  and  k21). Estimates of
unbound fraction for each drug (fu) were also used as
inputs.
PK parameters for each compound under study were
obtained from previously published population PK stud-
ies in critically ill patients, except for fu, which was derived
from the package insert for each drug; the mean and
standard deviation for each of these parameters have been
previously published[5,7]. Covariance matrices were
either reported in or were calculated from these studies
and were applied to the input pharmacokinetic variables
used in the simulations.
Monte Carlo simulation
A 5,000 trial Monte Carlo simulation (Crystal Ball 2000,
Decisioneering, Denver, CO, USA) was conducted for
each antimicrobial regimen using the pharmacokinetic
model in order to determine the regimen's probability of
target attainment (PTA) profile. PTA is the probability that
the regimen will meet or exceed a pre-defined pharmaco-
dynamic target at a given MIC dilution[8]. Here, PTA is
the proportion of the 5,000 trials in each simulation that
achieved the target level of a PD index at each MIC in dou-
bling dilutions from 0.008 to 128 µg/ml.
The target indices were selected based on the PD proper-
ties (i.e., time-dependent or concentration-dependent
killing) of the compound. As the four compounds mod-
eled here exhibit time-dependent killing, the proportion
of the dosing interval during which the concentration of
free (unbound) drug remains above the MIC is the appro-
priate PD index[9]. For the carbapenems (including imi-
penem), 40% fT>MIC was considered bactericidal; 50%
fT>MIC was considered bactericidal for piperacillin-tazo-
bactam and for the cephalosporins[9,10]. The PTA profile
was then determined for each regimen.
Cumulative Fraction of Response
CFR is the probability that the regimen will attain its PD
index against the specific population of organisms charac-
terized in the ISS Program. Each regimen's simulation-
derived PTA is multiplied by the percentage of isolates
found at each MIC dilution; the sum of these products is
the CFR[8]. For each scenario (all isolates in the primary
analysis or an individual species in the sub-analyses), this
process was applied to four MIC distributions, one from
each three-year interval, to obtain the CFR for each regi-
men during each interval.
A CFR of 90% was considered to be the threshold for
achieving reliable empiric therapy[11]. Confidence inter-
vals were calculated around each CFR result to provide a
measure of statistical significance; however, it is impor-
tant to consider these results in light of clinical signifi-
cance as well. The CFR for each interval can be compared
to illustrate trends in the ability of each regimen to
achieve its best killing effect. A p-value ≤ 0.05 indicates a
statistically significant trend across the four periods,
where lower CFRs in later periods reflect a decline in activ-
ity (higher CFRs would indicate an improvement). Confi-
dence intervals around each CFR probability were
calculated at α = 0.05 using the Newcombe-Wilson
method without correction for continuity[12]. Trends in
cumulative fraction of response for each regimen were
assessed using the Cochran-Armitage test for trend (SAS
version 9.0, Cary, NC, USA).
Results
Results of the primary analysis are presented in Table 2.
Against all species aggregated, imipenem demonstrated a
trend toward slightly improving activity over the four peri-
ods, and had predicted responses near 90%. Cefepime dis-
played a decreasing activity profile over time, though still
showing generally high predicted responses (80%–90%,
depending on dosing regimen). Ceftriaxone had relatively
low predicted response rates (< 52%) across all periods,
and no significant trend was detected. Piperacillin-tazo-
bactam 4.5 g q6h displayed the highest predicted
response among piperacillin-tazobactam regimens (80–
78%), with a trend toward decreasing activity. The less
aggressive piperacillin-tazobactam regimens (4.5 g q8h
and 3.375 g q6h) displayed lower CFRs and were stable to
trend.
Sub-analyses were conducted on two species which have
been shown in the literature to be highly pathogenic and
whose resistance is of current concern: the results for P.
aeruginosa and Acinetobacter spp. are displayed in Tables 3
and 4, respectively. Against both species, all active agents
showed significant declines in predicted CFR over time.
For P. aeruginosa, the greatest activity was observed with
higher doses of cefepime (particularly 2 g q8h). Against
Acinetobacter spp., imipenem displayed the most favorable
activity profile, with predicted CFRs >20% higher than
cefepime and piperacillin-tazobactam.
Discussion
We examined nosocomial isolates collected from ICUs in
the United States during a multi-year surveillance study in
order to assess the performance of antibiotics commonly
used to treat infections in this setting, and to identify anyAnnals of Clinical Microbiology and Antimicrobials 2007, 6:11 http://www.ann-clinmicrob.com/content/6/1/11
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trends in antimicrobial performance over time. Four
broad-spectrum agents were studied: cefepime, ceftriax-
one, imipenem and piperacillin-tazobactam. We used PK/
PD principles to predict the likelihood that each com-
pound and dose would achieve its maximum bactericidal
effect against the tested population of organisms, as meas-
ured by cumulative fraction of response. The Monte Carlo
simulation technique enables us to predict the microbio-
logical performance of different regimens while account-
ing for the variance in PK characteristics that such
regimens are likely to encounter in critically ill patients. It
should be noted that microbiological success is but one
part of clinical success in treating infection, as many fac-
tors – co-morbidities, immunocompetence, etc. – contrib-
ute to the ultimate recovery of a patient. However, we
have found that simulation-predicted microbiological
response does indeed correlate with clinical response[13].
As such, identifying trends in probable microbiological
success can provide useful insight into the clinical impli-
cations of changing resistance. We found moderate to
good predicted responses (80% CFR or better) to all spe-
cies aggregated as a group for three of the four compounds
examined, with low response rates predicted for ceftriax-
one. Response rates were dose-dependent, with more
aggressive doses yielding greater predicted response. As to
trend, imipenem's ability to achieve bactericidal effect
showed a slight statistical improvement over time,
whereas the effect of shifting MIC distributions on the
other compounds was reflected in stable or worsening
activity.
The examination of antibiotic performance against the
entire cohort of isolates in the ISS Program is useful as a
broad evaluation of continued efficacy to pathogens
encountered in the ICU; however, clinically significant
trends in any one species may be masked by the trend (or
Table 3: Cumulative fraction of response for various drug regimens against P. aeruginosa MICs collected from the Merck ICU 
Surveillance Study (ISS) Program, in four time intervals.
Antimicrobial agent: CFRa (%)
Time interval: 1993–1995b 1996–1998 1999–2001 2002–2004 p-value
Imipenem 500 mg q6h 81.6 81.9 79.5 78.5 <.0001
Imipenem 1 g q8h 81.9 82.0 79.8 78.7 <.0001
Ceftriaxone 1 g q24h 1.4 1.4 1.4 1.3 .6217
Ceftriaxone 2 g q24h 3.2 3.2 3.1 2.8 .2903
Cefepime 1 g q12h - 69.9 68.3 67.2 .0035
Cefepime 2 g q12h - 83.5 82.9 81.8 .0240
Cefepime 2 g q8h - 92.2 92.7 91.2 .0842
Pip-Tazo 3.375 g q6h - 75.9 74.0 73.3 .0024
Pip-Tazo 4.5 g q8h - 70.8 69.0 68.4 .0095
Pip-Tazo 4.5 g q6h - 79.6 77.5 76.7 .0004
aCFRs were calculated at 40% fT>MIC for imipenem and 50% fT>MIC for the other compounds.
bNo data for cefepime or pip-tazo was provided for 1993–1995.
Table 2: Cumulative fraction of response for various drug regimens against MICs collected from the Merck ICU Surveillance Study 
(ISS) Program, in four time intervals.
Antimicrobial agent: CFRa (%)
Time interval: 1993–1995b 1996–1998 1999–2001 2002–2004 p-value
Imipenem 500 mg q6h 87.0 87.7 88.2 90.6 <.0001
Imipenem 1 g q8h 86.8 87.3 87.9 90.2 <.0001
Ceftriaxone 1 g q24h 32.5 30.9 32.3 31.5 .6128
Ceftriaxone 2 g q24h 51.6 49.2 51.2 50.0 .3726
Cefepime 1 g q12h - 80.6 80.4 78.6 .0118
Cefepime 2 g q12h - 86.8 87.5 84.8 .0027
Cefepime 2 g q8h - 91.8 93.5 89.9 .0006
Pip-Tazo 3.375 g q6h - 76.6 77.3 75.1 .0667
Pip-Tazo 4.5 g q8h - 72.1 72.9 70.9 .1569
Pip-Tazo 4.5 g q6h - 79.4 79.9 77.5 .0175
aCFRs were calculated at 40% fT>MIC for imipenem and 50% fT>MIC for the other compounds.
bNo data for cefepime or piperacillin-tazobactam (pip-tazo) was provided for 1993–1995.Annals of Clinical Microbiology and Antimicrobials 2007, 6:11 http://www.ann-clinmicrob.com/content/6/1/11
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lack thereof) in the overall group. For this reason, the
study also examined two species individually: P. aerugi-
nosa and Acinetobacter species. Both species are implicated
in a variety of nosocomial infections (including pneumo-
nia, bacteremia, skin infections and others), and reports
of multi-drug resistant strains have been increasing[14]. P.
aeruginosa was the most prevalent species in the ISS Pro-
gram dataset, at 22% of tested isolates. This species is an
important nosocomial pathogen not only because of its
frequency, but also because it possesses intrinsic resist-
ance to many antimicrobial agents, and has the ability to
acquire both plasmid-mediated and chromosomal resist-
ance genes[15]. Acinetobacter spp. was the fifth most prev-
alent pathogen in the dataset (at 6%), but was modeled
individually because high levels of resistance have been
reported in Latin America and in some regions of the
United States[1,16]. Multi-drug resistance in these two
species is associated with increased mortality, and has
become sufficiently problematic in some locations that
alternative therapy using older and more toxic agents such
as polymyxins is sometimes considered the best option
[17-19].
Against P. aeruginosa, cefepime, imipenem and piperacil-
lin-tazobactam showed statistically significant declines in
CFR over time for all regimens except cefepime 2 g q8h.
This regimen also was clearly the most potent, with pre-
dicted CFRs >90%, where every other regimen had pre-
dicted CFRs <80% by the last time period. This suggests
that, while more aggressive dosing may enable a com-
pound to kill more reliably (i.e., with a greater probability
of success), this effect no longer holds once the potency of
the agent has sufficiently eroded. Overall, the magnitude
of the CFR declines for all the regimens over the 12-year
period of the study remains small, reflecting a steady,
although moderate, upward shift in the distribution of
MICs.
Against Acinetobacter spp., statistically significant declines
in CFR were observed for all regimens of cefepime, imi-
penem and piperacillin-tazobactam. Further, the magni-
tude of the decline across periods is much greater than
that observed against P. aeruginosa – on the order of 10%–
15% decline in CFR against the former species versus 2–
3% versus the latter. While both declines show statistically
significant trends, whether or not the low single digit
declines against P. aeruginosa are clinically significant is
debatable – that is, these declines in effectiveness are
probably noticed in some institutions more than others,
to the extent that the higher MICs observed here are not
evenly distributed among hospitals. However, the larger
declines in predicted efficacy against Acinetobacter are of
great enough magnitude that a clinical effect may com-
monly be seen. Indeed, cefepime and piperacillin-tazo-
bactam were predicted to have such low CFRs (<50% for
all regimens except cefepime 2 g q8h, with a predicted
CFR of 65%) as to be of little use clinically. Imipenem,
while showing declines in CFR over the four time periods,
is the only modeled agent with a high enough probability
of achieving its best bactericidal effect to be relied upon
clinically. These results reflect a species with rapidly
increasing MICs to the modeled compounds.
Conclusion
The MIC distributions of ICU pathogens to these com-
monly prescribed compounds have increased significantly
over time, and their effectiveness as measured by ability to
attain PD targets has declined. Statistically significant
declines in effectiveness were noted against P. aeruginosa
and Acinetobacter spp. for all regimens analyzed except for
ceftriaxone, which has no activity to these organisms.
Against P. aeruginosa, cefepime 2 g q8h remains a potent
choice for therapy; the therapeutic utility of imipenem
and piperacillin-tazobactam can be maximized by aggres-
sive dosing. Against Acinetobacter spp., declines in effec-
Table 4: Cumulative fraction of response for various drug regimens against Acinetobacter spp. MICs collected from the Merck ICU 
Surveillance Study Program (ISS), in four time intervals.
Antimicrobial agent: CFRa (%)
Time interval: 1993–1995b 1996–1998 1999–2001 2002–2004 p-value
Imipenem 500 mg q6h 94.5 91.5 84.8 84.6 <.0001
Imipenem 1 g q8h 94.2 92.0 86.2 86.1 <.0001
Ceftriaxone 1 g q24h 2.4 1.8 1.9 1.9 .1651
Ceftriaxone 2 g q24h 6.7 5.1 5.2 4.9 .0005
Cefepime 1 g q12h - 50.8 45.2 35.4 <.0001
Cefepime 2 g q12h - 65.8 63.1 49.7 <.0001
Cefepime 2 g q8h - 78.5 80.3 64.4 <.0001
Pip-Tazo 3.375 g q6h - 56.4 51.3 43.6 <.0001
Pip-Tazo 4.5 g q8h - 51.9 47.4 40.5 <.0001
Pip-Tazo 4.5 g q6h - 61.0 55.3 46.6 <.0001
aCFRs were calculated at 40% fT>MIC for imipenem and 50% fT>MIC for the other compounds.
bNo data for cefepime or pip-tazo was provided for 1993–1995.Publish with BioMed Central    and   every 
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tiveness are statistically (and likely clinically) significant.
Among the modeled agents, only imipenem remains a
viable therapeutic option against this organism; more
aggressive dosing of the other compounds does not bring
current effectiveness within range of earlier clinical relia-
bility, suggesting that an impact on outcomes may be
observed.
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